BioVie Upsizes Best-Efforts Offering to ~$75M, Warns of Deep Discount Risk

summarizeSummary

BioVie upsized its best-efforts offering to up to 56.4 million shares at an assumed $1.33 per share, targeting ~$70 million in net proceeds. The offering is highly dilutive for a company with a $15.4 million market cap and a going-concern warning, and the actual price may be lower than assumed.

check_boxKey Events · Financing and Capital Events · BIVI

• Offering Upsized to ~$75M

  Amendment No. 2 increases the offering to up to 56,390,977 shares plus up to 56,390,977 pre-funded warrants, targeting ~$70 million in net proceeds — a substantial increase from the prior ~$75 million target.

• Deep Discount Risk

  The assumed price of $1.33 is a 10% discount to the last reported sale, and the filing warns the actual public offering price may be at a further discount, increasing dilution for existing shareholders.

• No Minimum Offering

  This is a best-efforts offering with no minimum — the company may sell far fewer shares and raise significantly less than the target, jeopardizing its ability to fund operations.

• Going Concern Warning

  The company reiterates its going-concern warning, with cash of $13.1 million as of March 31, 2026, and a net loss of $16.4 million for the nine months ended March 31, 2026.

auto_awesomeAnalysis · BIVI · Life Sciences

In a dramatic escalation of its survival-mode capital raise, BioVie amended its S-1 to massively upsize a best-efforts offering to as many as 56.4 million shares plus pre-funded warrants, targeting roughly $70 million in net proceeds. The assumed price of $1.33 already reflects a 10% discount to the last reported sale, and the filing cautions that the actual price may be even lower. For a company with a $15.4 million market cap and a going-concern warning, this is a highly dilutive move. With no minimum on the offering, proceeds could fall far short of the target, leaving the company critically underfunded.